Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Faith L. CharlesDirector | CNS PharmaceuticalsCNSP | Open-market buy | 05/18 | 05/20 | 7,100 sh | $4.79 | $34,009 | No record |
CNS PharmaceuticalsCNSP | Open-market buy | 24/02/01 | 24/02/06 | 166,666 sh | $0.30 | $49,999.8 | +340.1% | |
CNS PharmaceuticalsCNSP | Open-market buy | 24/02/01 | 24/02/06 | 66,666 sh | $0.30 | $19,999.8 | +181.3% | |
Carl Anthony EvansDirector | CNS PharmaceuticalsCNSP | Open-market buy | 24/02/01 | 24/02/06 | 33,333 sh | $0.30 | $9,999.9 | +26666.4% |
Jerzy GumulkaDirector | CNS PharmaceuticalsCNSP | Open-market buy | 24/02/01 | 24/02/06 | 33,333 sh | $0.30 | $9,999.9 | +344.6% |
CNS PharmaceuticalsCNSP | Open-market buy | 23/08/22 | 23/08/23 | 27,000 sh | $1.27 | $34,290 | +276.3% | |
CNS PharmaceuticalsCNSP | Open-market buy | 23/08/16 | 23/08/16 | 2,750 sh | $1.80 | $4,950 | +5.9% | |
CNS PharmaceuticalsCNSP | Open-market sale10b5-1 plan | 22/12/06–23/03/28 | 23/08/01 | 94,298 sh17 trades | $1.41avg. | $133,114.14 | −37.6% | |
Jerzy GumulkaDirector | CNS PharmaceuticalsCNSP | Open-market buy | 23/04/19 | 23/04/21 | 2,500 sh | $1.70 | $4,250 | +34.9% |
CNS PharmaceuticalsCNSP | Open-market buy | 23/04/17 | 23/04/18 | 3,100 sh | $3.20 | $9,920 | +50.4% | |
Jerzy GumulkaDirector | CNS PharmaceuticalsCNSP | Open-market buy | 23/04/10 | 23/04/17 | 7,173 sh | $0.74 | $5,308.02 | No record |
CNS PharmaceuticalsCNSP | Open-market buy | 23/04/12 | 23/04/14 | 15,000 sh | $0.69 | $10,350 | +50.0% |